APRE
Price
$0.64
Change
+$0.01 (+1.59%)
Updated
Aug 21 closing price
Capitalization
8.06M
74 days until earnings call
Intraday BUY SELL Signals
STTK
Price
$7.53
Change
+$0.28 (+3.86%)
Updated
Aug 21 closing price
Capitalization
755.74M
79 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APRE vs STTK

APRE vs STTK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
APRE vs. STTK commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APRE is a Hold and STTK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (APRE: $0.64 vs. STTK: $7.53)
Brand notoriety: APRE and STTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APRE: 16% vs. STTK: 28%
Market capitalization -- APRE: $8.06M vs. STTK: $755.74M
APRE [@Biotechnology] is valued at $8.06M. STTK’s [@Biotechnology] market capitalization is $755.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APRE’s FA Score shows that 2 FA rating(s) are green whileSTTK’s FA Score has 0 green FA rating(s).

  • APRE’s FA Score: 2 green, 3 red.
  • STTK’s FA Score: 0 green, 5 red.
According to our system of comparison, APRE is a better buy in the long-term than STTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APRE’s TA Score shows that 4 TA indicator(s) are bullish while STTK’s TA Score has 3 bullish TA indicator(s).

  • APRE’s TA Score: 4 bullish, 4 bearish.
  • STTK’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, APRE is a better buy in the short-term than STTK.

Price Growth

APRE (@Biotechnology) experienced а -3.34% price change this week, while STTK (@Biotechnology) price change was +1.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

APRE is expected to report earnings on Nov 05, 2026.

STTK is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STTK($756M) has a higher market cap than APRE($8.06M). STTK YTD gains are higher at: 106.301 vs. APRE (-24.936). APRE has higher annual earnings (EBITDA): -12.56M vs. STTK (-49.02M). STTK has more cash in the bank: 90.4M vs. APRE (46.5M). APRE has less debt than STTK: APRE (0) vs STTK (2.89M). STTK has higher revenues than APRE: STTK (1M) vs APRE (0).
APRESTTKAPRE / STTK
Capitalization8.06M756M1%
EBITDA-12.56M-49.02M26%
Gain YTD-24.936106.301-23%
P/E RatioN/AN/A-
Revenue01M-
Total Cash46.5M90.4M51%
Total Debt02.89M-
FUNDAMENTALS RATINGS
APRE vs STTK: Fundamental Ratings
APRE
STTK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
8034
P/E GROWTH RATING
1..100
5100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APRE's Valuation (14) in the null industry is somewhat better than the same rating for STTK (64). This means that APRE’s stock grew somewhat faster than STTK’s over the last 12 months.

APRE's Profit vs Risk Rating (100) in the null industry is in the same range as STTK (100). This means that APRE’s stock grew similarly to STTK’s over the last 12 months.

APRE's SMR Rating (98) in the null industry is in the same range as STTK (99). This means that APRE’s stock grew similarly to STTK’s over the last 12 months.

STTK's Price Growth Rating (34) in the null industry is somewhat better than the same rating for APRE (80). This means that STTK’s stock grew somewhat faster than APRE’s over the last 12 months.

APRE's P/E Growth Rating (5) in the null industry is significantly better than the same rating for STTK (100). This means that APRE’s stock grew significantly faster than STTK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APRESTTK
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 12 days ago
75%
Bullish Trend 5 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 18 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
APRE
Daily Signal:
Gain/Loss:
STTK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EMGDX42.190.79
+1.91%
Allspring Emerging Markets Equity R6
EILGX17.090.14
+0.83%
Eaton Vance Atlanta Capital Focused Gr I
GSIYX24.110.11
+0.46%
Goldman Sachs GQG Ptnrs Intl Opps R6
RPFRX41.480.04
+0.10%
Davis Real Estate A
JDSRX26.25N/A
N/A
Janus Henderson Small Cap Value R

STTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STTK has been loosely correlated with VRTX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if STTK jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STTK
1D Price
Change %
STTK100%
+3.86%
VRTX - STTK
36%
Loosely correlated
+1.44%
ADCT - STTK
35%
Loosely correlated
+3.80%
PRME - STTK
34%
Loosely correlated
+4.63%
CELC - STTK
33%
Poorly correlated
+3.27%
BEAM - STTK
33%
Poorly correlated
+4.83%
More